AO252
Productby Coiled Therapeutics
Heard in 1 episode across 1 show since May 2026
An investigational therapeutic program licensed for worldwide development by Coiled Therapeutics; the excerpt presents it as a central drug-development asset.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 1 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
What experts have said about AO252
10 statements · 9 positive · 1 mixed
AO-252 reaches brain tissue at roughly blood-equivalent levels.
“Our ability to actually have pretty much on a 1-to-1 level of what the, the in the blood versus what's in the brain”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 11:03
AO-252 has an approximately 80% clinical benefit rate.
“our clinical benefit rate is at about 80%.”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 13:08
AO-252 reduced a tumor by 30% in a heavily pretreated patient.
“it still takes 30% of the tumor down.”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 13:41
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring AO252, newest first
